Search results
Search results from www.aesgp.eu
| Ingredient | ATC Level 1 | ATC Level 2 | Year Of Switch | Country | Status | Additional Information |
|---|---|---|---|---|---|---|
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Argentina | Rx | — |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Australia | OTC | Switched from S4 (prescription) to S3 (pharmacist only) in 2013. Effective 1 October 2015, approval of Appendix H entry, allowing direct-to-consumer advertising. Effective 1 February 2016, switch from S3 to S2 (pharmacy only) for esomeprazole in 20mg or less per dosage unit for the relief of gastro-oesophageal reflux disease, when in packs containing not more than 7 days' supply. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2012 | Austria | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Belgium | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. No OTC product currently available. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Bulgaria | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2016 | Canada | OTC | For the 14-day treatment for frequent heartburn at a daily dose of 20mg. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Chile | Rx | — |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | China | Rx | — |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Colombia | OTC | Maximum strength 10mg in capsules. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Croatia | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Czech Republic | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Denmark | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Estonia | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Finland | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | France | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. Maximum 280mg per pack. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Germany | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Greece | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Hungary | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Ireland | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. Supply through pharmacies only. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Italy | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Japan | Rx | — |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Lithuania | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Mexico | — | No information. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | New Zealand | — | No information. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Norway | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Philippines | — | No information. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Poland | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Portugal | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Romania | Rx | Not recommended for children below 12 years old. Adults - depending on the affliction - 20mg/40 mg once a day |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Russia | — | No information. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Singapore | — | No information. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Slovak Republic | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Slovenia | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | South Korea | — | No information. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Spain | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. No product currently marketed as OTC medicine. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | Sweden | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults over 18 years. Recommended daily dose: one 20 mg gastroresistant tablet or capsule. Available in 20mg gastro-resistant capsules or tablets. Maximum pack size 28 units, maximum duration of treatment: 2 weeks. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Switzerland | Rx | — |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | The Netherlands | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. UAD distribution status (Pharmacy and drugstore only). In February 2016, esomeprazole was allowed for AV distribution status (General sale) under the following conditions: for adults only and maximum 7 tablets of maximum 20mg. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2013 | UK | OTC | Esomeprazole 20mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 26 August 2013. It is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Recommended daily dose: one 20mg gastroresistant tablet. Maximum duration of treatment: 2 weeks. Reclassified from pharmacy to general sale (GSL) in January 2015. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | 2014 | USA | OTC | Frequent heartburn, acid reducer. Daily dose 20mg, in adults aged 18 and over. |
| Esomeprazole | A Alimentary tract and metabolism. Alimentary tract and metabolism | A02. Drugs for acid related disorders | — | Venezuela | Rx | — |
- 41 ingredients